- Length
- 860 aa
- Mass
- 95.4 kDa
- Annotated
- 2026-06-13
100 papers in source corpus
21 papers cited in narrative
21 extracted findings
Mechanistic narrative
Synthesis pass · prose summary of the discoveries below
Parse failed — see logs
Mechanism profile
Synthesis pass · controlled-vocabulary classification · explore literature graph →
No controlled-vocabulary terms were assigned to this entry.
Evidence
Reading pass · 21 per-paper findings extracted from the source corpus
| Year | Finding | Method | Journal | Conf | PMIDs |
|---|---|---|---|---|---|
| 2001 | Disabled-2 (Dab2) phosphotyrosine-binding domain binds peptides containing the FXN-PXY sequence found in the intracellular domains of LDLR family members, required for receptor internalization. Dab2 transiently colocalizes with LDLR in clathrin-coated pits but is absent from endosomes and lysosomes. The p96 Dab2 isoform (but not p67) binds the alpha-adaptin subunit of AP-2 via DPF motifs, and overexpression of p96 disrupts AP-2 localization, suggesting Dab2 acts as an adaptor regulating LDLR trafficking through clathrin-coated pits. | Peptide binding assays, colocalization by fluorescence microscopy, Co-IP with AP-2, overexpression/dominant-negative experiments | Traffic (Copenhagen, Denmark) | High | 11247302 |
| 2016 | The CCC (COMMD/CCDC22/CCDC93) and WASH complexes are required for endosomal sorting and recycling of LDLR back to the cell surface. Inactivation of either complex causes LDLR mislocalization, increased lysosomal degradation of LDLR, and impaired LDL uptake. COMMD1-deficient dogs and liver-specific Commd1 knockout mice have elevated plasma LDL cholesterol. Mutations in CCDC22 (causing X-linked intellectual disability) and in WASH component KIAA0196 (strumpellin) are associated with hypercholesterolaemia in humans. | Liver-specific knockout mice (Commd1), patient genetics, siRNA knockdown, LDLR localization by immunofluorescence, LDL uptake assays, plasma cholesterol measurements | Nature communications | High | 26965651 |
| 2014 | ZFP36L1 and ZFP36L2 RNA-binding proteins bind specifically to the 3'-UTR of LDLR mRNA and recruit the CCR4-NOT deadenylase complex, destabilizing LDLR mRNA. Upon ERK activation, p90 ribosomal S6 kinase (RSK) directly phosphorylates the C-terminal regions of ZFP36L1 and ZFP36L2, causing dissociation of the CCR4-NOT complex and stabilization of LDLR mRNA, thereby increasing LDLR protein levels. | Proteomic pulldown of LDLR mRNA 3'-UTR binding proteins, phosphorylation assays, LDLR mRNA stability assays, antisense oligonucleotide disruption of ZFP36L1/L2–LDLR mRNA interaction | Nucleic acids research | High | 25106868 |
| 2012 | IDOL (inducible degrader of LDLR) is an E3 ubiquitin ligase whose expression is transcriptionally induced by the cholesterol-sensing nuclear receptor LXR. When cellular sterol levels rise, activated LXR induces IDOL, which ubiquitinates LDLR and targets it for lysosomal degradation, thereby limiting cholesterol uptake. This LXR-IDOL-LDLR feedback pathway is independent of the SREBP pathway. | Biochemical ubiquitination assays, LXR agonist treatment, LDLR degradation assays, structural studies of IDOL-LDLR interaction | Arteriosclerosis, thrombosis, and vascular biology | High | 22936343 |
| 2011 | EGFRvIII activates PI3K/SREBP-1 signaling to upregulate LDLR expression, promoting tumor cell survival through increased cholesterol uptake in glioblastoma. Targeting LDLR with the LXR agonist GW3965 causes IDOL-mediated LDLR degradation and increases ABCA1 cholesterol efflux transporter expression, promoting GBM tumor cell death in vivo. | GBM cell lines, xenograft models, EGFRvIII/PI3K pathway manipulation, LXR agonist treatment, LDLR protein quantification | Cancer discovery | Medium | 22059152 |
| 2015 | USP2 deubiquitylase interacts with IDOL E3 ubiquitin ligase and promotes IDOL deubiquitylation, paradoxically stabilizing IDOL protein while markedly attenuating IDOL-mediated degradation of LDLR. USP2 forms a tri-partite complex with IDOL and LDLR, and in this context promotes deubiquitylation of LDLR itself, preventing its lysosomal degradation. Loss of USP2 reduces LDLR protein in an IDOL-dependent manner and limits LDL uptake. | Genetic screen, Co-IP, ubiquitylation assays, LDL uptake assays, USP2 knockdown/overexpression | Circulation research | High | 26666640 |
| 2008 | PCSK9 gain-of-function mutants (D374H, D374Y, D129N, N425S, R496W) reduce cell-surface LDLR protein when secreted from transfected cells and added to lymphocytes. Aspartate at position 374 of PCSK9 is critical for potent LDLR degradation. Approximately 35% of PCSK9-mediated LDLR reduction occurs via an ARH-independent pathway (demonstrated in ARH-deficient lymphocytes that cannot internalize LDLR), indicating PCSK9 can act at the cell surface. | Conditioned medium from transfected HEK293T cells applied to lymphocytes, FACS quantification of cell-surface LDLR, mutagenesis of PCSK9 at residue 374, ARH-null lymphocyte experiments | Atherosclerosis | High | 19081568 |
| 2025 | PCSK9 promotes LDLR degradation by blocking acidic pH-induced conformational change in the LDLR extracellular domain that normally allows LDLR to interact with SNX17 (sorting nexin 17) through its intracellular domain for recycling. Knockdown of SNX17 abolishes LDLR recycling, causing accelerated lysosomal degradation, and also abolishes PCSK9-mediated LDLR degradation. FH sequence variations that disrupt LDLR recycling (SNX17 interaction) are unresponsive to PCSK9 or PCSK9 inhibitors. | SNX17 knockdown, LDLR knockout mice and cells, reconstitution with LDLR variants, in vitro acidic pH conformational assays, Co-IP, in vivo mouse experiments | Circulation | High | 40071387 |
| 2018 | In the absence of LDLR, AMPK phosphorylates ALDH2 at threonine 356, enabling its nuclear translocation. Nuclear ALDH2 interacts with HDAC3 to repress transcription of ATP6V0E2 (a lysosomal proton pump protein), impairing lysosomal function, autophagy, and oxidized LDL degradation, promoting foam cell formation. The cytosolic C-terminus of LDLR directly interacts with AMPK, blocking ALDH2 phosphorylation and nuclear translocation. | ALDH2/LDLR double knockout mice, AMPK phosphorylation assays, Co-IP of LDLR C-terminus with AMPK, nuclear fractionation, HDAC3 interaction, ATP6V0E2 transcription assays, lysosomal function assays | The Journal of clinical investigation | High | 30375985 |
| 2007 | LDLR and VLDLR are selectively expressed in mature myelinating oligodendrocytes in the postnatal central nervous system, with expression progressively downregulated after P15, suggesting a role for LDLR-mediated cholesterol uptake in myelin sheath formation. | Immunohistochemistry, developmental expression analysis in spinal cord and brain regions | Developmental dynamics | Low | 17685481 |
| 2019 | LDLR contains an FVIII-binding site and LDLR polymorphisms (c.1773C/T and c.81C/T) are associated with distinct pharmacokinetic parameters of Factor VIII concentrates in hemophilia A patients, suggesting LDLR influences FVIII clearance through its intracellular distribution and FVIII binding behavior. | Two-compartment PK modeling of FVIII concentrates in 33 hemophilia A patients, LDLR genotyping, regression analysis | Journal of thrombosis and haemostasis | Low | 31055871 |
| 2024 | LDLR serves as a direct entry receptor for Crimean-Congo hemorrhagic fever virus (CCHFV). The ligand-binding domain (LBD) of LDLR is necessary for CCHFV infection. LDLR binds directly to CCHFV glycoprotein Gc with high affinity, supporting virus attachment and internalization via clathrin-mediated endocytosis. Genetic knockout of LDLR impairs infection in human, monkey, and mouse cells, restored by ectopic LDLR expression. Soluble sLDLR-Fc or anti-LDLR blocking antibodies impair CCHFV infection. | LDLR genetic knockout and reconstitution, direct binding assays (CCHFV Gc to LDLR LBD), soluble sLDLR-Fc inhibition, anti-LDLR blocking antibody, in vivo mouse CCHFV infection | Cell research | High | 38182887 |
| 2024 | LDLR functions as an entry receptor for multiple alphaviruses (GETV, SFV, RRV, BEBV). The interaction is mediated by the ligand-binding domain (LBD) of LDLR, specifically the CR4 and CR5 domains, and the E2-E1 spike of the virus. Mutations in CR4 and CR5 of LDLR-LBD reduce viral entry by more than 20-fold. GST-LBD fusion protein inhibits GETV infection in vitro and in vivo. | LDLR ectopic expression, viral binding and internalization assays, LDLR LBD mutagenesis, antibody blocking, GST-LBD inhibition in vitro and in vivo | Nature communications | High | 38245515 |
| 2019 | LDLR variants D482H and C667F are retained in the ER and fail to traffic to the plasma membrane, as confirmed by N-glycosylation profile analysis. ER-retained mutants associate with ER quality control components, induce ER stress (evidenced by spliced XBP-1 mRNA), and are stabilized by proteasome inhibitors, demonstrating that class II LDLR trafficking-deficient variants are degraded via ER-associated degradation (ERAD). | Transfection of LDLR mutants in cells, N-glycosylation analysis, XBP-1 splicing assay, Co-IP with ER quality control components, proteasome inhibitor treatment, confocal microscopy | FEBS open bio | Medium | 31587492 |
| 2007 | Berberine increases LDLR transcriptional activity via the JNK pathway: berberine induces c-Jun binding to a c-Jun binding site in the LDLR promoter, and this transcriptional activation is inhibited by the JNK inhibitor SP600125. This is distinct from the previously described berberine-induced ERK-dependent LDLR mRNA stabilization. | RT-PCR, luciferase reporter assay with LDLR promoter, EMSA (electrophoretic mobility shift assay) for c-Jun binding, JNK inhibitor treatment | Biochemical and biophysical research communications | Medium | 17767919 |
| 2020 | LDLR deficiency (Ldlr knockout) results in enhanced caspase-1-dependent cleavage of GSDMD, NLRP3-mediated maturation and release of IL-1β and IL-18, and increased neuronal pyroptosis following cerebral ischemia/reperfusion. Pharmacological blockade of NLRP3 with CY-09 substantially reduced neuronal pyroptosis in Ldlr-/- mice, placing LDLR upstream of the NLRP3 inflammasome in ischemic neuroinflammation. | Ldlr knockout mice, middle cerebral artery occlusion model, NLRP3 pharmacological inhibitor (CY-09), oxygen-glucose deprivation in vitro, histological and biochemical analysis of pyroptosis markers | Journal of neuroinflammation | Medium | 33153475 |
| 2020 | LDLR loss leads to LDL accumulation, increased apoptosis, TGF-β1 production, and fibroblast-like endothelial and alveolar type II cell accumulation, contributing to pulmonary fibrosis. In vitro, LDL treatment induced apoptosis and TGF-β1 production, while LDLR knockdown induced fibroblast-like cell accumulation and ET-1 expression in endothelial/epithelial cells. Pharmacological restoration of LDLR with atorvastatin and alirocumab inhibited LDL elevation and mitigated bleomycin-induced pulmonary fibrosis. | Ldlr-/- mice (bleomycin model), LDLR knockdown in vitro, LDL treatment of cells, pharmacological LDLR restoration | Clinical and translational medicine | Medium | 35083881 |
| 2024 | EGF stimulation induces an extracellular proximity association between EGFR and LDLR at the cell surface, as detected by ecTurboID proximity labeling. EGF stimulation also changes the extracellular interactome of LDLR, increasing its proximity with proteins that regulate EGFR signaling. | Extracellular TurboID (ecTurboID) proximity labeling combined with mass spectrometry, EGF stimulation | Science signaling | Low | 39499777 |
| 2021 | Macropeptide 13PCSK9i, identified via affinity-based screen of macrocyclic peptides, binds PCSK9 at a unique allosteric pocket (distinct from the LDLR-binding face) and partially disrupts the PCSK9-LDLR interaction via an induced-fit mechanism. In mice, 13PCSK9i reduces plasma cholesterol and increases hepatic LDLR density in a dose-dependent manner. | In vitro translation macrocyclic peptide affinity screen, SPR binding, structure-based design, in vivo mouse dosing, hepatic LDLR quantification | Cell chemical biology | Medium | 34547225 |
| 2020 | LDLR regulates cisplatin sensitivity in epithelial ovarian cancer via an LDLR→LPC (lyso-phosphatidylcholine)→FAM83B→FGFRs signaling axis. LDLR knockdown sensitizes EOC cells to cisplatin while LDLR overexpression causes cisplatin insensitivity, both in vitro and in vivo. | siRNA knockdown and overexpression of LDLR in EOC cells, cisplatin sensitivity assays in vitro and xenograft models, trans-omics (lipidomics + transcriptomics) | Endocrine-related cancer | Medium | 31815680 |
| 2020 | Soluble LDLR (sLDLR), the shed ectodomain of transmembrane LDLR, is generated by ADAM-17 (a disintegrin-and-metalloproteinase-17) cleavage. ADAM-17 is activated by inflammation, and shedding reduces cellular uptake of triglyceride-loaded lipoproteins, causing their accumulation in circulation. This mechanistically links plasma sLDLR to hypertriglyceridemia. | Review/mechanistic synthesis of published data; ADAM-17 as the identified shedding enzyme | Lipids in health and disease | Low | 32014013 |
Source papers
Stage 0 corpus · 100 papers · ranked by NIH iCite citations
| Year | Title | Journal | Citations | PMID |
|---|---|---|---|---|
| 2014 | Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. | Nature | 532 | 25487149 |
| 2018 | The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. | JACC. Basic to translational science | 398 | 30623143 |
| 2011 | An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. | Cancer discovery | 377 | 22059152 |
| 2012 | Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. | The Yale journal of biology and medicine | 303 | 22461740 |
| 2014 | PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. | Current opinion in lipidology | 286 | 25110901 |
| 2001 | Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2. | Traffic (Copenhagen, Denmark) | 223 | 11247302 |
| 2016 | CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL. | Nature communications | 165 | 26965651 |
| 2016 | Do the Apoe-/- and Ldlr-/- Mice Yield the Same Insight on Atherogenesis? | Arteriosclerosis, thrombosis, and vascular biology | 160 | 27386935 |
| 2020 | Low-density lipoprotein receptor (LDLR) regulates NLRP3-mediated neuronal pyroptosis following cerebral ischemia/reperfusion injury. | Journal of neuroinflammation | 134 | 33153475 |
| 2009 | Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. | Journal of lipid research | 125 | 19174369 |
| 2005 | Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. | Clinical chemistry and laboratory medicine | 115 | 15899668 |
| 2001 | Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice. | Arteriosclerosis, thrombosis, and vascular biology | 112 | 11597927 |
| 2012 | Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis. | Arteriosclerosis, thrombosis, and vascular biology | 102 | 22936343 |
| 2014 | MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/-mice. | Thrombosis and haemostasis | 90 | 25008143 |
| 2021 | Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model. | Theranostics | 89 | 33456582 |
| 2014 | Targeted disruption of LDLR causes hypercholesterolemia and atherosclerosis in Yucatan miniature pigs. | PloS one | 88 | 24691380 |
| 2018 | Acetaldehyde dehydrogenase 2 interactions with LDLR and AMPK regulate foam cell formation. | The Journal of clinical investigation | 80 | 30375985 |
| 2014 | ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK-RSK pathway. | Nucleic acids research | 78 | 25106868 |
| 2002 | The UMD-LDLR database: additions to the software and 490 new entries to the database. | Human mutation | 78 | 12124988 |
| 2018 | Hyperlipidemia induces typical atherosclerosis development in Ldlr and Apoe deficient rats. | Atherosclerosis | 73 | 29459263 |
| 2007 | Berberine-induced LDLR up-regulation involves JNK pathway. | Biochemical and biophysical research communications | 72 | 17767919 |
| 2020 | Dietary Choline or Trimethylamine N-oxide Supplementation Does Not Influence Atherosclerosis Development in Ldlr-/- and Apoe-/- Male Mice. | The Journal of nutrition | 71 | 31529091 |
| 2013 | A variant in LDLR is associated with abdominal aortic aneurysm. | Circulation. Cardiovascular genetics | 70 | 24046328 |
| 2014 | On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. | Atherosclerosis | 63 | 25544176 |
| 2014 | Macrophage deficiency of Akt2 reduces atherosclerosis in Ldlr null mice. | Journal of lipid research | 60 | 25240046 |
| 2018 | Small Molecule Inhibitors of the PCSK9·LDLR Interaction. | Journal of the American Chemical Society | 57 | 29378408 |
| 2008 | Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells. | Atherosclerosis | 55 | 19081568 |
| 2018 | Bergapten inhibits liver carcinogenesis by modulating LXR/PI3K/Akt and IDOL/LDLR pathways. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 54 | 30227322 |
| 2024 | LDLR is an entry receptor for Crimean-Congo hemorrhagic fever virus. | Cell research | 52 | 38182887 |
| 2019 | Therapeutic targets of hypercholesterolemia: HMGCR and LDLR. | Diabetes, metabolic syndrome and obesity : targets and therapy | 47 | 31686875 |
| 2015 | The Deubiquitylase USP2 Regulates the LDLR Pathway by Counteracting the E3-Ubiquitin Ligase IDOL. | Circulation research | 46 | 26666640 |
| 2019 | Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients. | Atherosclerosis | 45 | 31491741 |
| 2021 | Platycodin D inhibits autophagy and increases glioblastoma cell death via LDLR upregulation. | Molecular oncology | 40 | 33931944 |
| 2006 | Inflammation and skin cholesterol in LDLr-/-, apoA-I-/- mice: link between cholesterol homeostasis and self-tolerance? | Journal of lipid research | 40 | 17071966 |
| 2015 | Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression. | The Journal of nutritional biochemistry | 39 | 26320675 |
| 2024 | LDLR is used as a cell entry receptor by multiple alphaviruses. | Nature communications | 38 | 38245515 |
| 2021 | Identification of a PCSK9-LDLR disruptor peptide with in vivo function. | Cell chemical biology | 38 | 34547225 |
| 2010 | LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives. | International archives of medicine | 37 | 21144047 |
| 2022 | Intervention with isoleucine or valine corrects hyperinsulinemia and reduces intrahepatic diacylglycerols, liver steatosis, and inflammation in Ldlr-/-.Leiden mice with manifest obesity-associated NASH. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology | 34 | 35830259 |
| 2025 | PCSK9 Promotes LDLR Degradation by Preventing SNX17-Mediated LDLR Recycling. | Circulation | 33 | 40071387 |
| 2022 | Astragaloside IV Relieves Atherosclerosis and Hepatic Steatosis via MAPK/NF-κB Signaling Pathway in LDLR-/- Mice. | Frontiers in pharmacology | 32 | 35264962 |
| 2021 | The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia. | Genes | 32 | 33418990 |
| 2016 | Is Western Diet-Induced Nonalcoholic Steatohepatitis in Ldlr-/- Mice Reversible? | PloS one | 32 | 26761430 |
| 2020 | Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a. | Journal of translational medicine | 31 | 32398139 |
| 2007 | Selective expression of LDLR and VLDLR in myelinating oligodendrocytes. | Developmental dynamics : an official publication of the American Association of Anatomists | 31 | 17685481 |
| 2022 | LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis. | Clinical and translational medicine | 30 | 35083881 |
| 2024 | Cholesterol homeostasis confers glioma malignancy triggered by hnRNPA2B1-dependent regulation of SREBP2 and LDLR. | Neuro-oncology | 28 | 38070488 |
| 2018 | Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA. | Scientific reports | 28 | 30385871 |
| 2018 | CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice. | Molecular metabolism | 28 | 30553772 |
| 2018 | A Deep Intronic Variant in LDLR in Familial Hypercholesterolemia. | Circulation. Genomic and precision medicine | 28 | 30562117 |
| 2009 | Identification and functional characterization of LDLR mutations in familial hypercholesterolemia patients from Southern Italy. | Atherosclerosis | 28 | 20045108 |
| 2022 | Oxidative Stress and Lipid Accumulation Augments Cell Death in LDLR-Deficient RPE Cells and Ldlr-/- Mice. | Cells | 27 | 36611838 |
| 2021 | Gypenoside LVI improves hepatic LDL uptake by decreasing PCSK9 and upregulating LDLR expression. | Phytomedicine : international journal of phytotherapy and phytopharmacology | 26 | 34380071 |
| 2001 | Low density lipoprotein receptor (LDLR) gene mutations in Canadian subjects with familial hypercholesterolemia, but not of French descent. | Human mutation | 26 | 11668627 |
| 2019 | Endoplasmic reticulum quality control of LDLR variants associated with familial hypercholesterolemia. | FEBS open bio | 25 | 31587492 |
| 2023 | Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice. | International journal of molecular sciences | 24 | 37239841 |
| 2007 | Genetic study evaluating LDLR polymorphisms and Alzheimer's disease. | Neurobiology of aging | 24 | 17239995 |
| 2024 | MaiJiTong granule attenuates atherosclerosis by reducing ferroptosis via activating STAT6-mediated inhibition of DMT1 and SOCS1/p53 pathways in LDLR-/- mice. | Phytomedicine : international journal of phytotherapy and phytopharmacology | 23 | 38569295 |
| 2022 | Increased LDL receptor by SREBP2 or SREBP2-induced lncRNA LDLR-AS promotes triglyceride accumulation in fish. | iScience | 23 | 35811843 |
| 2018 | Bidirectional effects of IL-10+ regulatory B cells in Ldlr-/- mice. | Atherosclerosis | 23 | 30500604 |
| 2015 | Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment. | Pharmacogenomics | 23 | 26427613 |
| 2024 | Remodeling Intestinal Microbiota Alleviates Severe Combined Hyperlipidemia-Induced Nonalcoholic Steatohepatitis and Atherosclerosis in LDLR-/- Hamsters. | Research (Washington, D.C.) | 22 | 38694198 |
| 2018 | Hyperhomocysteinemia and hyperandrogenemia share PCSK9-LDLR pathway to disrupt lipid homeostasis in PCOS. | Biochemical and biophysical research communications | 22 | 29660344 |
| 2018 | Inhibition of PCSK9D374Y/LDLR Protein-Protein Interaction by Computationally Designed T9 Lupin Peptide. | ACS medicinal chemistry letters | 22 | 30996774 |
| 2021 | Discovery of Novel Small Molecule Inhibitors Disrupting the PCSK9-LDLR Interaction. | Journal of chemical information and modeling | 21 | 34553597 |
| 2014 | Meta-analysis of low density lipoprotein receptor (LDLR) rs2228671 polymorphism and coronary heart disease. | BioMed research international | 21 | 24900971 |
| 2021 | Dietary phosphatidylcholine supplementation reduces atherosclerosis in Ldlr-/- male mice2. | The Journal of nutritional biochemistry | 20 | 33705949 |
| 2020 | LDLR-mediated lipidome-transcriptome reprogramming in cisplatin insensitivity. | Endocrine-related cancer | 20 | 31815680 |
| 2016 | Prolonged Intake of Dietary Lipids Alters Membrane Structure and T Cell Responses in LDLr-/- Mice. | Journal of immunology (Baltimore, Md. : 1950) | 20 | 27183636 |
| 2012 | Fish oil and indomethacin in combination potently reduce dyslipidemia and hepatic steatosis in LDLR(-/-) mice. | Journal of lipid research | 20 | 22847176 |
| 2012 | Loss of Id3 increases VCAM-1 expression, macrophage accumulation, and atherogenesis in Ldlr-/- mice. | Arteriosclerosis, thrombosis, and vascular biology | 20 | 23042815 |
| 2023 | Tanshinone IIA alleviates atherosclerosis in LDLR-/- mice by regulating efferocytosis of macrophages. | Frontiers in pharmacology | 19 | 37886125 |
| 2021 | Small, Smart, and LDLR-Specific Micelles Augment Sorafenib Therapy of Glioblastoma. | Biomacromolecules | 19 | 34677048 |
| 2019 | Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates. | Journal of thrombosis and haemostasis : JTH | 19 | 31055871 |
| 2015 | Hypercholesterolemia and neurodegeneration. Comparison of hippocampal phenotypes in LDLr knockout and APPswe/PS1dE9 mice. | Experimental gerontology | 19 | 25797218 |
| 2008 | Two mutations in LDLR gene were found in two Chinese families with familial hypercholesterolemia. | Molecular biology reports | 19 | 19020990 |
| 2020 | PTH/PTHrP Receptor Signaling Restricts Arterial Fibrosis in Diabetic LDLR-/- Mice by Inhibiting Myocardin-Related Transcription Factor Relays. | Circulation research | 18 | 32160132 |
| 2019 | Berberine decreases plasma triglyceride levels and upregulates hepatic TRIB1 in LDLR wild type mice and in LDLR deficient mice. | Scientific reports | 18 | 31666640 |
| 2022 | Allicin and Capsaicin Ameliorated Hypercholesterolemia by Upregulating LDLR and Downregulating PCSK9 Expression in HepG2 Cells. | International journal of molecular sciences | 17 | 36430776 |
| 2021 | PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis. | Frontiers in cardiovascular medicine | 17 | 34692791 |
| 2020 | Regulation of intestinal LDLR by the LXR-IDOL axis. | Atherosclerosis | 17 | 33190106 |
| 2016 | Genistein upregulates LDLR levels via JNK-mediated activation of SREBP-2. | Food & nutrition research | 17 | 27211318 |
| 2015 | Hematopoietic knockdown of PPARδ reduces atherosclerosis in LDLR-/- mice. | Gene therapy | 17 | 26204499 |
| 2024 | Rare Genetic Variants in LDLR, APOB, and PCSK9 Are Associated With Aortic Stenosis. | Circulation | 16 | 39222019 |
| 2016 | Enhanced Megakaryopoiesis and Platelet Activity in Hypercholesterolemic, B6-Ldlr-/-, Cdkn2a-Deficient Mice. | Circulation. Cardiovascular genetics | 16 | 27098250 |
| 2022 | Functional profiling of LDLR variants: Important evidence for variant classification: Functional profiling of LDLR variants. | Journal of clinical lipidology | 15 | 35568682 |
| 2021 | LDLR variants functional characterization: Contribution to variant classification. | Atherosclerosis | 15 | 34167030 |
| 2020 | In Silico Insights into Protein-protein Interaction Disruptive Mutations in the PCSK9-LDLR complex. | International journal of molecular sciences | 15 | 32106405 |
| 2020 | Binding of Macrophage Receptor MARCO, LDL, and LDLR to Disease-Associated Crystalline Structures. | Frontiers in immunology | 15 | 33363539 |
| 2016 | Compound heterozygous LDLR variant in severely affected familial hypercholesterolemia patient. | Acta biochimica Polonica | 15 | 27878139 |
| 2024 | Sexual dimorphism in atherosclerotic plaques of aged Ldlr-/- mice. | Immunity & ageing : I & A | 14 | 38698438 |
| 2023 | Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR-/- mice. | Scientific reports | 14 | 36894641 |
| 2021 | Characterizing the Role of Glycogen Synthase Kinase-3α/β in Macrophage Polarization and the Regulation of Pro-Atherogenic Pathways in Cultured Ldlr-/- Macrophages. | Frontiers in immunology | 14 | 34394077 |
| 2017 | Analysis of LDLR variants from homozygous FH patients carrying multiple mutations in the LDLR gene. | Atherosclerosis | 14 | 28645073 |
| 2023 | Microglia contribute to cognitive decline in hypercholesterolemic LDLr-/- mice. | Journal of neurochemistry | 13 | 37694813 |
| 2021 | Pcsk9 Knockout Aggravated Experimental Apical Periodontitis via LDLR. | Journal of dental research | 13 | 34036816 |
| 2020 | The enigma of soluble LDLR: could inflammation be the key? | Lipids in health and disease | 13 | 32014013 |
| 2020 | A systematic review of LDLR, PCSK9, and APOB variants in Asia. | Atherosclerosis | 13 | 32629184 |
| 2019 | Gpihbp1 deficiency accelerates atherosclerosis and plaque instability in diabetic Ldlr-/- mice. | Atherosclerosis | 13 | 30721842 |
| 2024 | Extracellular proximal interaction profiling by cell surface-targeted TurboID reveals LDLR as a partner of liganded EGFR. | Science signaling | 12 | 39499777 |
Missed literature
Know a paper Affinage missed for LDLR? Flag it for the maintainers and the community.
No submissions yet.